Creo Medical’s FY24: A Surgical Strike on Growth and Stability
If you’ve ever watched a skilled surgeon navigate a complex procedure with precision, you’ll appreciate the delicate balance Creo Medical has struck in its latest results. The AIM-listed medtech firm just dropped its FY24 numbers, and there’s plenty to dissect. Let’s grab our endoscopic tools and take a closer look.
The headline act: 74% core revenue growth
Creo’s Core Technology revenue jumped a whopping 74% year-on-year to £4m. This turbocharged growth comes courtesy of their flagship Speedboat UltraSlim device, which has become the Swiss Army knife of endoscopic surgery. Over 5,000 procedures globally (3,000+ in its debut year) suggest clinicians are voting with their scalpels.
- Total group revenue held steady at £30.7m (£30.8m in FY23)
- Cash position strengthened to £8.7m (up from £3m in FY23)
- £5m annualised cost savings achieved – the financial equivalent of removing a tumour without damaging surrounding tissue
Strategic manoeuvres: Playing chess with the balance sheet
Creo’s management has been busy in the corporate theatre:
1. The Micro-Tech partnership
September’s sale of 51% of Creo Medical Europe to Chinese giant Micro-Tech was a masterstroke:
- €30m cash injection (post-period)
- Retains 49% stake for ongoing profit share
- Opens doors to APAC markets and potential co-development projects
2. Portfolio pruning
December’s decision to sell Aber Electronics completes the shift from R&D darling to commercial operator. As CEO Craig Gulliford notes: “The transition from development to commercial profitability is the most challenging phase for any company.”
Clinical wins: More than just numbers
The real story lives in operating theatres:
- NHS case study: 130 procedures at East Kent Hospitals showed 87% reduction in patient stays and £687k savings
- World first: Robotic-guided lung ablation using MicroBlate Flex (with Intuitive Surgical)
- Royal seal: King’s Award for Innovation collected at Windsor Castle
The toolkit expansion
Creo’s product pipeline is hitting its stride:
- Speedboat Notch: Enhanced upper GI version launched April 2025
- SpydrBlade Flex: The “harmonic scalpel at the end of a flexible scope” making waves at St Mark’s Hospital
- CROMA platform: Becoming the Android of endoscopic energy systems
Looking ahead: FY25 guidance
Management’s scalpel stays sharp for 2025:
- 40-60% Core Technology revenue growth target
- Full £5m cost savings to flow through
- MicroBlate Flex expected to start generating recurring revenue
New Chairman Kevin Crofton strikes a cautiously optimistic note: “We remain diligent and flexible to respond to challenges, steadfast in our mission to improve lives.”
The investment thesis: Scalpel or Swiss Army knife?
Creo’s transformation story contains all the classic medtech ingredients:
- ✓ Transition from R&D burn to commercial scale
- ✓ Strategic partnerships de-risking expansion
- ✓ NHS validation providing rubber-stamp credibility
But as any surgeon knows, precision matters. The 74% growth comes off a small base, and macroeconomic headwinds haven’t disappeared. That said, with gross margins improving (46.6% from 40.2% ex-Kamaptive) and the balance sheet stabilised, Creo appears to be suturing its early-stage risks closed.
As the NHS scrambles to clear backlogs and global healthcare seeks cost-effective solutions, Creo’s technology sits at the perfect crossroads. The FY24 results suggest they’re not just building better scalpels – they’re redesigning the operating theatre.
